GoodRx received an upgrade to a neutral rating following its first-quarter earnings report.
The upgrade comes after the company showed a return to subscriber growth in its recent quarterly results. Interest in weight loss medications boosted specialty subscriptions and direct revenue from pharmaceutical partners. Despite concerns over concentration risk in the business, GoodRx is shifting its model strategically. The stock trades at around four times adjusted EBITDA, with risk viewed as already priced in by the market.
